Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system
This study revealed potential AEs of Zuranolone, confirming known safety information about Zuranolone, providing comprehensive data for medical practice and public health decision-making, and laying the foundation for further clinical research. It also provides more comprehensive and updated evidence for the clinical safety of Zuranolone.
Authors
- Yufeng Peng (ORCID: https://orcid.org/0000-0003-0942-3141)
- Kang Zou (ORCID: https://orcid.org/0000-0002-4959-1951)
- Zixin Luo
- Duoqin Huang (ORCID: https://orcid.org/0009-0000-5952-7884)
- Shaoying Zeng
- Xi Gong
Institutions
- Gannan Medical University (CN)
- Jiangxi Pingxiang People's Hospital (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fpsyt.2025.1517773
- Primary Topic
- Maternal Mental Health During Pregnancy and Postpartum
- Type
- article
- Field-Weighted Citation Impact
- 0.00